The global emergence of novel coronavirus disease 2019 (COVID-19) has underlined the requirement for rapid assays with high sensitivity and specificity for detection of infection and further to understand the molecular complexity of the disease.
Explore how our customers have used the Evosep One to develop an effective screening assay and comprehensive understanding of the disease.
the current situation for clinical proteomics
Professor Akhilesh Pandey now from the Mayo Clinic, Rochester, US talks with Nicolai Bache, Head of Applications at Evosep about the current situation for clinical proteomics and what is looming on the horizon.
With the ongoing COVID-19 pandemic the need for robust solutions for clinical proteomics are urgently required.
STANDARDIZATION IS KEY
The Evosep One serves as a robust and standardized front-end solution, which can be paired with the most widely used mass spectrometers. It allows for up to 300 samples analyzed per day and is therefore ideally suited for testing a large sample cohort with a specific clinical assay.
SENSITIVE AND SPECIFIC TARGETED ASSAY FOR DETECTION OF COVID-19
This publication describes the development of an automated antibody capture-based workflow coupled to a targeted FAIMS-PRM assay on an Orbitrap Exploris 480 MS developed by the Akhilesh Pandey group at the Mayo Clinic, Rochester, US from the analysis of more than 700 nasopharyngeal swab samples were analyzed.
The key advantage of the assay, which allows for 200 samples analyzed per day, is the high specificity and comparable sensitivity to the gold standard RT-PCR method for the diagnosis of SARS-CoV-2. The method can be adapted for detection of novel variants of SARS-CoV-2 as they appear and can easily be deployed at routine clinical laboratories with mass spectrometry instrumentation.
COMPREHENSIVE MULTI-OMICS UNDERSTANDING OF COVID-19
This publication from multiple research groups in Germany describes the molecular functions of viral proteins and their interactions with the host proteome of SARS-CoV-2. It serves as a resource describing the interplay between different omics levels.
The impact of viral infection on the proteome and phosphoproteome were analyzed in a time-resolved manner using the Evosep One with data-independent analysis on a Q Exactive HF-X. The analysis revealed key pathways perturbed during the infection identifying potential vulnerable points of SARS-CoV-2 that could be targeted by well-characterized selective drugs for antiviral therapies.
SERUM PROTEOMICS AND ANALYSIS OF RED BLOOD CELLS FROM COVID-19 PATIENTS
In these two studies, researchers from University of Colorado performed proteomics analysis of Covid-19 patients and healthy control individuals.
By using the Evosep One coupled to a timsTOF Pro, they measured the proteomes of red blood cells (RBC) and identified increased glycolysis in RBCs from COVID-19 patients, accompanied by increased oxidation of key structural proteins.
They also did a serum proteomics analysis stratified by the degree of inflammation, represented by IL-6 levels as a marker of disease severity. Their results highlight a clear increase in the levels of inhibitory components of the fibrinolytic cascade in severe COVID-19 disease, providing potential clues related to the etiology of coagulopathic complications in COVID-19 and paving the way for potential therapeutic interventions, such as the use of pro-fibrinolytic agents.
find all publications, product brochures and presentations with Evosep One
The five STANDARD METHODS
For the Evosep One
HOW FAR WILL YOU GO?
More research on COVID-19
Here you can see publications available on COVID-19 featuring Evosep One. For a full overview of publications published using the Evosep One Technology visit our Literature room here
|Title||Subject||Material||Year||Summary||Institute||Evosep method||MS instrumentation||Learn More|
|Serum Proteomics in COVID-19 Patients: Altered Coagulation and Complement Status as a Function of IL-6 Level||Clinical research, Covid-19, DDA, Serum||Publication||2020||This publication describes a serum proteomics analysis of COVID-19 patients, stratified by the degree of inflammation, represented by IL-6 levels. It highlights an increase in the levels of inhibitory components of the fibrinolytic cascade in severe COVID-19 disease, providing potential therapeutic interventions, such as the use of pro-fibrinolytic agents.||Bruker timsTOF Pro|
|Multi-level proteomics reveals host-perturbation strategies of SARS-CoV-2 and SARS-CoV||Clinical research, Covid-19, DIA, PTM||Publication||2020||This publication describes the molecular functions of viral proteins and their interactions with the host proteome of SARS-CoV-2. The impact of viral infection on the proteome and phosphoproteome were analyzed in a time-resolved manner by DIA. The analysis revealed key pathways perturbed during the infection identifying potential vulnerable points of SARS-CoV-2.||30 SPD, 60 SPD||Thermo Q Exactive HF-X|
|Development of mass spectrometry-based targeted assay for direct detection of novel SARS-CoV-2 coronavirus from clinical specimens||Clinical research, Covid-19, DDA, Targeted workflow||Publication||2020||This publication by the Akhilesh Pandey group describes a targeted FAIMS-PRM assay on an Orbitrap Exploris 480 MS. More than 700 nasopharyngeal swab samples were analyzed with high specificity and comparable sensitivity to the gold standard RT-PCR method for the diagnosis of SARS-CoV-2.||100 SPD, 200 SPD||Thermo Orbitrap Exploris 480|
|Evidence of Structural Protein Damage and Membrane Lipid Remodeling in Red Blood Cells from COVID-19 Patients||Clinical research, Covid-19, DDA||Publication||2020||In this study, researchers from University of Colorado led by Angelo D’Alessandro, performed proteomics analysis of Covid-19 patients and healthy control individuals. They measured the proteomes of red blood cells (RBC) and identified increased glycolysis in RBCs from COVID-19 patients, accompanied by increased oxidation of key structural proteins.||Bruker timsTOF Pro|
|Seroconversion stages COVID19 into distinct pathophysiological states||Clinical research, Covid-19, Plasma||Publication||2020||In this study, researchers from University of Colorado led by Joaquin M. Espinosa, found highly variable seroconversion status among hospitalized Covid-19 patients. Their results support the existence of distinct pathophysiological states, with seroconversion status being potentially useful as a surrogate marker of underlying processes.||30 SPD||Bruker timsTOF Pro|
|Fluvastatin mitigates SARS-CoV-2 infection in human lung cells||Clinical research, Covid-19||Publication||2020||Clinical data of patients suffering from COVID-19 have indicated that statin therapy, used to treat high cholesterol, is associated with a better clinical outcome. A collaboration led by Gisa Gerold investigated the effect of statins on SARS-CoV-2 infection in human lung cells and found that fluvastatin inhibited coronavirus infection, while other tested statins did not.||Extended method||Bruker timsTOF Pro|
|The Host Interactome of Spike Expands the Tropism of SARS-CoV-2||Clinical research, Covid-19, Protein interaction||Publication||2021||This publication from the Yates lab, investigates the host interactome determining whether a SARS-CoV-2 infection is productive. They find an “S2 only” dependent, alternative infection of additional cell types with SARS-CoV-2 may impact vaccination strategies and provide a molecular explanation for a severe or prolonged progression of disease in select COVID-19 patients.||30 SPD||Bruker timsTOF Pro|
|High-resolution longitudinal serum proteome trajectories in COVID-19 reveal patients-specific seroconversion||Automation, Clinical research, Covid-19||Publication||2021||This publication from OmicEra Diagnostics, describes alterations of the serum proteome during COVID-19 using a scalable plasma proteome profiling workflow. It comprises the most detailed longitudinal protein trajectories during hospitalization, based on one of the largest MS-based body fluid proteomics efforts with a total of 720 plasma serum samples.||60 SPD||Bruker timsTOF Pro|
|Covid-19 research with Evosep One||Covid-19, DIA, Technology||Webinar||2021||This webinar is part of our Evosep webinar series and hosted by Nicolai Bache, Evosep. Angela McArdle and Mathias Trost discuss their use of the Evosep One technology in their development of rapid Covid-19 assays.||60 SPD||Thermo Orbitrap Exploris 480|
|The COVIDome Explorer Researcher Portal||Clinical research, Covid-19, DDA, Plasma||Publication||2021||Researchers from University of Colorado led by Joaquin M. Espinosa, have created a user-friendly researcher portal enabling easy access and real-time analysis of matched multi-omics datasets for COVID-19, termed the COVIDome Explorer. They illustrate the use through a multi-omics analysis of biosignatures associated with C-reactive protein (CRP), an established marker of poor prognosis in COVID-19.||30 SPD||Bruker timsTOF Pro|
|A blood atlas of COVID-19 defines hallmarks of disease severity and specificity||Covid-19, DDA, Plasma||Publication||2021||This publication is a major collaboration led by the Knight group at University of Oxford describing the hallmarks of Covid-19 severity and specificity. It is an integrative multi-omics analysis, where the Evosep One was used for measuring 340 plasma proteomes providing excellent patient stratification.||100 SPD||Bruker timsTOF Pro|
|Exploitation of the Secretory Pathway by SARS-CoV-2 Envelope||Covid-19, DDA, Protein interaction||Publication||2021||This publication by the Carlton group investigates the mechanism, by which Coronaviral Eenvelope proteins achieves its steady state localization to the Endoplasmic Reticulum Golgi Intermediate Compartment. They use proximity biotinylation to define the vicinal proteome of wild type and ER-restricted versions of Envelope.||30 SPD||Thermo Orbitrap Fusion Lumos|
|Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study||Covid-19, Plasma||Publication||2021||This resource by the IMmunoPhenotyping Assessment in a Covid-19 cohort (IMPACC) describes a longitudinal study designed to enroll 1000 hospitalized patients with Covid-19. The Evosep One will be used to analyze depleted plasma samples.||Bruker timsTOF Pro|